Seema Verma, former CMS head, joins Oracle

Seema Verma, the former head of the Centers for Medicare and Medicaid Services (CMS) under the Trump administration, has joined Oracle as senior vice president and general manager of Life Sciences, the company announced. 

In this new role, Verma will lead the Oracle Life Sciences and Oracle Cerner Enviza lines of business. She most recently served as a senior advisor to private equity firms Cressy & Co. and TPG.

During her time at CMS, Verma was a proponent of healthcare transparency to give patients more information about their healthcare options. This included a rule that required hospitals to post the list prices of their most common procedures. She also served on the White House COVID-19 Task Force, helping in the widespread adoption of telehealth, Hospital at Home and no-cost vaccines for the entire country.

“Seema has a proven track record of success in both public and private sector healthcare,”  Mike Sicilia, executive vice president of Oracle Global Industries, said in a statement on April 20. “Because of this, she has a unique understanding of how to bring together those on the cutting edge of innovation and those in charge of regulation to help our customers make critical medical breakthroughs and bring new therapies to market.”

Prior to her time at CMS, Verma founded and sold a national consulting company and worked as a vice president for policy and planning for a public hospital, public health department, and health system. In addition, she served on the Board of Directors for Lumeris, Monogram, Wellsky, ClaimsXten, Lifestance and ShiftKey. 

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.